Subcutaneous Injection Sites for Enoxaparin
Enoxaparin should be administered subcutaneously in the anterolateral or posterolateral abdominal wall. 1
Specific Injection Technique
The FDA-approved drug label specifies that enoxaparin is administered via subcutaneous injection into the abdominal wall 1. The guidelines consistently reference "subcutaneous administration" throughout multiple clinical contexts 2, 3, with the abdominal wall being the standard site.
Key Technical Points:
- Preferred sites: Anterolateral and posterolateral aspects of the abdominal wall
- Alternating sides: Rotate between left and right sides of the abdomen with each injection to minimize local complications
- Avoid: Do not inject into areas with bruising, scarring, or within 2 inches of the umbilicus
Clinical Context from Guidelines
The major cardiovascular guidelines consistently describe enoxaparin as being given "subcutaneously" for various indications 2, 3:
- For STEMI/NSTEMI: 1 mg/kg subcutaneously every 12 hours (or 1.5 mg/kg once daily for VTE) 2, 3
- For VTE prophylaxis: 40 mg subcutaneously once daily 4
- For VTE treatment: 1 mg/kg twice daily or 1.5 mg/kg once daily 4
Important Caveats:
Bruising is common at injection sites and represents an expected side effect rather than a complication requiring site change 5, 6. Research shows that injection duration (10 vs 30 seconds) does not significantly affect bruising size 5, though local cold-hot pack application may reduce bruising 6.
Avoid intramuscular injection: The subcutaneous route is critical—accidental intra-arterial injection has resulted in severe complications including expanding hematomas requiring surgical intervention 7.
Alternative routes exist but are limited: While IV enoxaparin (infused over 30 minutes) has been studied in critically ill pediatric patients and shown comparable efficacy 8, this is not standard practice and subcutaneous administration remains the primary route for routine clinical use.
Practical Considerations
The abdominal wall site is preferred because:
- Consistent absorption (though critically ill patients may have reduced absorption compared to stable patients 9)
- Easy access for self-administration
- Large surface area allowing site rotation
- Minimal interference with daily activities
For patients with obesity (BMI ≥40 kg/m²), the abdominal subcutaneous site remains appropriate, though higher doses may be required to achieve therapeutic anti-Xa levels 10.